/IDRA
IDRA Stock - Idera Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$0.42-23.04%
$0.13 (-23.04%) • Jan 17
52
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.4
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.80
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.47
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IDRA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.42 – $0.43
TARGET (TP)$0.49
STOP LOSS$0.39
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.00
52W High$16.00
52W Low$0.42
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $1.45M | $662,000 |
| Gross Profit | N/A | N/A | N/A | $1.45M | $662,000 |
| Gross Margin | N/A | N/A | N/A | 100.0% | 100.0% |
| Operating Income | $-27,818,000 | $-27,673,000 | $-36,687,000 | $-46,067,000 | $-60,956,000 |
| Net Income | $-23,360,000 | $98.08M | $-112,662,000 | $-84,558,000 | $-59,881,000 |
| Net Margin | N/A | N/A | N/A | -5839.6% | -9045.5% |
| EPS | $-7.18 | $31.55 | $-56.63 | $-33.66 | $-38.27 |
Company Overview
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
IDRABeat Rate
50%
Last 16 quarters
Avg Surprise
+43.1%
EPS vs Estimate
Beats / Misses
8/8
Last 12 quarters
Latest EPS
$-2935.64
Q2 2023
EPS Surprise History
Q3 21
-1316.7%
$-2.55vs$-0.18
Q4 21
-1458.3%
$-1.87vs$-0.12
Q1 22
-1136.4%
$-1.36vs$-0.11
Q2 22
-1136.4%
$-1.36vs$-0.11
Q3 22
No data
Q4 22
No data
Q1 23
No data
Q2 23
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2023 | Jun 29, 2023 | — | $-2935.64 | — | — |
Q1 2023 | Mar 29, 2023 | — | $-3.30 | — | — |
Q4 2022 | Nov 14, 2022 | — | $1.02 | — | — |
Q3 2022 | Aug 9, 2022 | — | $-0.10 | — | — |
Q2 2022 | May 5, 2022 | $-0.11 | $-1.36 | -1136.4% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $-0.11 | $-1.36 | -1136.4% | ✗ MISS |
Q4 2021 | Nov 8, 2021 | $-0.12 | $-1.87 | -1458.3% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-0.18 | $-2.55 | -1316.7% | ✗ MISS |
Q2 2021 | Apr 29, 2021 | $-0.21 | $45.22 | +21633.3% | ✓ BEAT |
Q1 2021 | Mar 1, 2021 | $-0.23 | $-35.87 | -15495.7% | ✗ MISS |
Q4 2020 | Oct 29, 2020 | $-0.22 | $-0.59 | -168.2% | ✗ MISS |
Q3 2020 | Aug 4, 2020 | $-0.39 | $-0.72 | -84.6% | ✗ MISS |
Q2 2020 | Apr 30, 2020 | $-0.41 | $0.22 | +153.7% | ✓ BEAT |
Q1 2020 | Mar 12, 2020 | $-0.35 | $-1.76 | -402.9% | ✗ MISS |
Q4 2019 | Nov 6, 2019 | $-0.46 | $-0.39 | +15.2% | ✓ BEAT |
Q3 2019 | Aug 8, 2019 | $-0.42 | $-0.39 | +7.1% | ✓ BEAT |
Q2 2019 | May 2, 2019 | $-0.46 | $-0.40 | +13.0% | ✓ BEAT |
Q1 2019 | Mar 6, 2019 | $-0.51 | $-0.45 | +11.8% | ✓ BEAT |
Q4 2018 | Nov 6, 2018 | $-0.58 | $-0.43 | +25.9% | ✓ BEAT |
Q3 2018 | Aug 2, 2018 | $-0.82 | $-0.59 | +28.0% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about IDRA
What is IDRA's current stock price?
Idera Pharmaceuticals, Inc. (IDRA) is currently trading at $0.42 per share. The stock has moved -23.04% today.
What is the analyst price target for IDRA?
No analyst price targets are currently available for this stock.
What sector is Idera Pharmaceuticals, Inc. in?
Idera Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IDRA's market cap?
Idera Pharmaceuticals, Inc. has a market capitalization of N/A, making it a small-cap company.
Does IDRA pay dividends?
No, Idera Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALLK
Allakos Inc.
$0.33
Mkt Cap: $0.0B
ANGN
Angion Biomedica Corp.
$1.00
Mkt Cap: $0.0B
ANPC
AnPac Bio-Medical Science Co., Ltd.
$4.30
Mkt Cap: $0.0B
FRLN
Freeline Therapeutics Holdings plc
$6.49
Mkt Cap: $0.0B
GMTX
Gemini Therapeutics, Inc.
$1.35
Mkt Cap: $0.0B
LMNL
Liminal BioSciences Inc.
$8.50
Mkt Cap: $0.0B
LSB
LakeShore Biopharma Co., Ltd
$0.63
Mkt Cap: $0.0B
MRNS
Marinus Pharmaceuticals, Inc.
$0.55
Mkt Cap: $0.0B
SER
Serina Therapeutics, Inc.
$2.75
Mkt Cap: $0.0B
VINC
Vincerx Pharma, Inc.
$0.01
Mkt Cap: $0.0B
Explore stocks similar to IDRA for comparison